CytomX Therapeutics, Inc. $CTMX Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP lifted its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 44.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,168,961 shares of the biotechnology company’s stock after buying an additional 1,585,976 shares during the quarter. Wellington Management Group LLP owned approximately 2.37% of CytomX Therapeutics worth $19,384,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of CTMX. Wells Fargo & Company MN boosted its holdings in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the period. Invesco Ltd. bought a new position in shares of CytomX Therapeutics in the second quarter worth $32,000. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics during the 1st quarter valued at about $39,000. May Hill Capital LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $46,000. Finally, Nierenberg Investment Management Company LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter valued at $47,081. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CTMX shares. Zacks Research cut shares of CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. JPMorgan Chase & Co. dropped their price objective on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Finally, Wolfe Research assumed coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They set an “outperform” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.90.

CytomX Therapeutics Price Performance

Shares of CTMX opened at $3.71 on Monday. The stock’s 50-day moving average price is $3.49 and its 200 day moving average price is $3.96. The firm has a market capitalization of $808.41 million, a price-to-earnings ratio of -7.42 and a beta of 2.14. CytomX Therapeutics, Inc. has a 12-month low of $1.90 and a 12-month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%.The firm had revenue of $1.42 million during the quarter, compared to the consensus estimate of $12.39 million. Equities research analysts expect that CytomX Therapeutics, Inc. will post -0.4 EPS for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.